165 related articles for article (PubMed ID: 15193251)
41. Efficacy and Limitations of F-18-fluoro-2-deoxy-D-glucose Positron Emission Tomography to Differentiate Between Malignant and Benign Bone and Soft Tissue Tumors.
Miwa S; Mochizuki T; Yamamoto N; Shirai T; Hayashi K; Takeuchi A; Inatani H; Igarashi K; Higuchi T; Abe K; Taniguchi Y; Aiba H; Ikeda H; Tsuchiya H
Anticancer Res; 2018 Jul; 38(7):4065-4072. PubMed ID: 29970532
[TBL] [Abstract][Full Text] [Related]
42. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
[TBL] [Abstract][Full Text] [Related]
43. Pairwise comparison of 18F-FDG and 18F-FCH PET/CT in prostate cancer patients with rising PSA and known or suspected second malignancy.
How Kit N; Dugué AE; Sevin E; Allouache N; Lesaunier F; Joly F; Aide N
Nucl Med Commun; 2016 Apr; 37(4):348-55. PubMed ID: 26642435
[TBL] [Abstract][Full Text] [Related]
44. Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study.
Hara T; Kosaka N; Suzuki T; Kudo K; Niino H
Chest; 2003 Sep; 124(3):893-901. PubMed ID: 12970014
[TBL] [Abstract][Full Text] [Related]
45. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
46. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization.
Choi JY; Lee KS; Kim HJ; Shim YM; Kwon OJ; Park K; Baek CH; Chung JH; Lee KH; Kim BT
J Nucl Med; 2006 Apr; 47(4):609-15. PubMed ID: 16595494
[TBL] [Abstract][Full Text] [Related]
47. The prevalence and clinical significance of (18) F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma.
Lin M; Wong C; Lin P; Shon IH; Cuganesan R; Som S
Hematol Oncol; 2011 Jun; 29(2):67-74. PubMed ID: 20635328
[TBL] [Abstract][Full Text] [Related]
48. Role of ¹⁸F-FDG PET/CT in differentiation of a benign lesion and metastasis on the ribs of cancer patients.
Choi HS; Yoo IeR; Park HL; Choi EK; Kim SH; Lee WH
Clin Imaging; 2014; 38(2):109-14. PubMed ID: 24361174
[TBL] [Abstract][Full Text] [Related]
49. The use of dual-phase 18F-FDG PET in characterizing thyroid incidentalomas.
Hsiao YC; Wu PS; Chiu NT; Yao WJ; Lee BF; Peng SL
Clin Radiol; 2011 Dec; 66(12):1197-202. PubMed ID: 21907336
[TBL] [Abstract][Full Text] [Related]
50. F-18 FDG in conjunction with 11C-choline PET/CT in the diagnosis of hepatocellular carcinoma.
Wu HB; Wang QS; Li BY; Li HS; Zhou WL; Wang QY
Clin Nucl Med; 2011 Dec; 36(12):1092-7. PubMed ID: 22064078
[TBL] [Abstract][Full Text] [Related]
51. Comparative study of the value of dual tracer PET/CT in evaluating breast cancer.
Tateishi U; Terauchi T; Akashi-Tanaka S; Kinoshita T; Kano D; Daisaki H; Murano T; Tsuda H; Macapinlac HA
Cancer Sci; 2012 Sep; 103(9):1701-7. PubMed ID: 22632272
[TBL] [Abstract][Full Text] [Related]
52. Utility of 18F-FDG PET/CT uptake patterns in Waldeyer's ring for differentiating benign from malignant lesions in lateral pharyngeal recess of nasopharynx.
Chen YK; Su CT; Chi KH; Cheng RH; Wang SC; Hsu CH
J Nucl Med; 2007 Jan; 48(1):8-14. PubMed ID: 17204693
[TBL] [Abstract][Full Text] [Related]
53. A stepwise approach using metabolic volume and SUVmax to differentiate malignancy and dysplasia from benign colonic uptakes on 18F-FDG PET/CT.
Oh JR; Min JJ; Song HC; Chong A; Kim GE; Choi C; Seo JH; Bom HS
Clin Nucl Med; 2012 Jun; 37(6):e134-40. PubMed ID: 22614211
[TBL] [Abstract][Full Text] [Related]
54. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions.
Aoki J; Watanabe H; Shinozaki T; Takagishi K; Ishijima H; Oya N; Sato N; Inoue T; Endo K
Radiology; 2001 Jun; 219(3):774-7. PubMed ID: 11376267
[TBL] [Abstract][Full Text] [Related]
55. Monitoring bone and soft-tissue tumors after carbon-ion radiotherapy using ¹⁸F-FDG positron emission tomography: a retrospective cohort study.
Yanagawa T; Saito K; Kiyohara H; Ohno T; Nakano T; Takagishi K
Radiat Oncol; 2015 Dec; 10():259. PubMed ID: 26691334
[TBL] [Abstract][Full Text] [Related]
56. FDG-PET/CT for diagnosis of primary ovarian cancer.
Kitajima K; Suzuki K; Senda M; Kita M; Nakamoto Y; Onishi Y; Maeda T; Yoshikawa T; Ohno Y; Sugimura K
Nucl Med Commun; 2011 Jul; 32(7):549-53. PubMed ID: 21407140
[TBL] [Abstract][Full Text] [Related]
57. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
58. Comparison of lesion-to-cerebellum uptake ratios and standardized uptake values in the evaluation of lung nodules with 18F-FDG PET.
Obrzut S; Pham RH; Vera DR; Badran K; Hoha CK
Nucl Med Commun; 2007 Jan; 28(1):7-13. PubMed ID: 17159543
[TBL] [Abstract][Full Text] [Related]
59. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
60. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
